Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of bendamustine
hydrochloride when given together with idarubicin in treating older patients with previously
untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Drugs used in
chemotherapy, such as bendamustine hydrochloride or idarubicin, work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium